With 20 offices across the U.S., Haskell is located within the country’s critical life sciences clusters, and its significant presence in Latin America and Asia-Pacific provides the scale needed to support multinational clients. 

September 22, 2022

Cross-Disciplinary Expertise Benefits Life Sciences Facilities Projects

Haskell offers EPC solutions in pharmaceuticals, biotechnology, medical devices and technology, and high-purity active pharmaceutical ingredients.

Share
Tweet
Share
Share

Producing the best possible patient outcome is the universal focus in healthcare and, by extension, those in life science fields. Haskell has decades of experience providing solutions for health systems and a considerable resume in biopharmaceuticals and advanced manufacturing. 

Yet as it has expanded its presence in support of those who provide care, Haskell’s greatest attributes continue to be its most basic. 

“As Haskell continues to grow within the life sciences market, the company must stick to its four main strengths: project safety, financial stability, customer advocacy, and longevity,” said Ken Anthony, Vice President of Haskell’s Life Sciences Division. “Haskell’s industry-leading safety record speaks for itself.

“Haskell has gained tremendous financial stability through solid project performance and continuous revenue growth. This enables our firm to take on larger, more complex engineer, procure, construct (EPC) projects in advanced manufacturing. We are recognized by our customers as a trusted advisor for their most challenging projects, and when it comes to Life Science projects, building a trusted team is key to success. Finally, Haskell has longevity. As an employee-owned company, Haskell has greater stability than publicly held or single-owner companies. We are strong because of our team members, many that have been with the firm for their entire careers.” 

The Life Sciences team is focused on four sectors: pharmaceuticals, biotechnology, medical devices and technology, and high-purity active pharmaceutical ingredients (API). These four focus areas require expertise in Current Good Manufacturing Practices (cGMP) design, contamination-control strategy and implementation, design/procure/build for Commissioning, Qualification and Validation (CQV) and efficient transition to operations, and deep knowledge in managing subcontractors through project management and control methods that are at the heart of Haskell’s practice.

With 20 offices across the U.S., Haskell is near most of the country’s life sciences clusters, and its significant presence in Latin America and Asia-Pacific provides the scale needed to support multinational clients. Further, a specialized segment of its process engineering team has a unique focus on crafting hygienic solutions for complex manufacturing systems, and developing innovative ways to incorporate the benefits of CIP and SIP into the appropriate environments has defined its work for more than 40 years. Recent industry clients include Genetech, Amgen, GSK, and Eli Lilly. 

“Life Sciences is a continuation of Haskell’s past pharmaceutical work, with a significant number of projects over the past 15 years,” Anthony said. “Coupled with our deep knowledge and experience in healthcare facilities, Haskell is well-positioned to focus our services that require regulatory oversight, review, and approval by the Food and Drug Administration (FDA) and the Biomedical Research and Development Authority (BARDA).  

“Continuing to grow in life sciences is a natural extension of Haskell’s work in health care. Haskell already has rich experience in process systems, cGMP design, clean-in-place (CIP), sterilization-in-place (SIP), clean rooms, various laboratories and specialized space design, and advanced manufacturing. The resources and expertise in our Life Sciences Division, and the addition of key personnel brings experience in Cell Culture, Gene Therapy, and advanced laboratory design to complement our excellent design staff and subject matter experts.” 

Given its comprehensive design and construction expertise, Haskell takes a holistic approach rto facilities solutions, combining full-service life sciences work with the expertise to deliver the non-regulated portions of projects, such as industrial wastewater treatment systems, central utility plants, site selection and preparation, and other infrastructure-related requirements to enable renovation or greenfield projects. 

Supply chain disruptions caused the pandemic created demand to reshore or near-shore critical high-purity API production facilities, the factories that supply the basic chemical ingredients necessary for drug and equipment manufacturing. Medical device manufacturers are also under pressure to produce at record levels and have found weakness in their reliance for global supply of the materials needed to integrate their products.

“Many of these companies will be looking to relocate to North America, whether in the U.S., Mexico, or another country in the region,” Anthony said. “They need reputable EPC expertise to help them plan their facilities, select and prepare suitable sites and design, procure, and construct their new facilities. In fact, Haskell is already working on projects for two multinational pharmaceutical companies in Mexico. Our strong regional expertise is a great resource for life sciences projects in the area.” 

Anthony, an industry veteran with more than 30 years of experience leading capital projects for advanced manufacturing projects in biotech, pharma, semiconductor, engineered materials and food and beverage, stressed the importance of understanding clients’ challenges. He said he looked forward to partnering with other firms in the Life Sciences space to offer the best possible solutions with the customer’s needs always at the center of the discussion.

Contact Haskell’s Life Sciences team to collaborate about your facilities needs in the pharmaceutical, biotechnology, medical device and technology or high-purity API sectors. 

Frequently Asked Questions

“Good Manufacturing Practice” (GMP) standards are administered by the Food and Drug Administration (FDA) and other regulating bodies. The “c” in cGMP stands for “current,” and brings to the table the most up-to-date standards available. A facility designed to support cGMP standards will consistently and constantly maintain the best practices in its design, monitoring, and controls to ensure the highest possible quality of products manufactured there.

In contrast to the broader process manufacturing sector, the life sciences industry is subject to a complex and evolutionary regulatory system that affects the way plant infrastructure must be procured and integrated. Further, adherence to GMPs and cGMPs requires the need for clean-room technologies, which must work seamlessly with the process infrastructure housed therein.

Yes, renovation of brownfield, or existing, facilities are increasingly popular to overcome a lack of vacant green space in areas that are desirable for lab development. Repurposing existing buildings, such as warehouses, office structures and shopping malls, also can often be cost-effective and allow greater speed to market. Consideration must be given to proper dimensioning for air-handling systems, efficient physical layout and power and utility needs.

Haskell delivers more than $1 billion annually in Architecture, Engineering, Construction (AEC) and Consulting solutions to assure certainty of outcome for complex capital projects worldwide. Haskell is a global, fully integrated, single-source design-build and EPC firm with over 2,000 highly specialized, in-house design, construction and administrative professionals across industrial and commercial markets. With 20+ office locations around the globe, Haskell is a trusted partner for global and emerging clients.

Related News & Insights